CSCI(Delisted)
Cosciens BiopharmaยทNASDAQ
--
--(--)
Is CSCI undervalued or overvalued?
- CSCI scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its -62.75% ROE, -199.56% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 0.00% earnings growth, these metrics solidify its Neutral investment rating.
